Our results provide supporting evidence for the crucial role of IL-6 in the generation of colonic inflammation, as IL-6 blockade delayed disease onset and attenuated colitis-associated symptoms in DSS-treated mice (Fig. 2A). This evidence concerns the gene IL6 and colitis.